<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>radioligand therapy &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/radioligand-therapy/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Mon, 13 Oct 2025 14:29:24 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.0</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>radioligand therapy &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>Radioligand Therapy’s Impact on Neuroendocrine Tumors</title>
		<link>https://bioengineer.org/radioligand-therapys-impact-on-neuroendocrine-tumors/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Mon, 13 Oct 2025 14:29:02 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[Gastroenteropancreatic Neuroendocrine Tumors]]></category>
		<category><![CDATA[Neuroendocrine Tumor Treatment]]></category>
		<category><![CDATA[precision oncology]]></category>
		<category><![CDATA[radioligand therapy]]></category>
		<category><![CDATA[Targeted Radiation Therapy]]></category>
		<guid isPermaLink="false">https://bioengineer.org/radioligand-therapys-impact-on-neuroendocrine-tumors/</guid>

					<description><![CDATA[In the evolving landscape of oncology, the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) remains a crucial challenge. Understanding the mechanisms and advancements in treatment modalities can greatly influence patient outcomes. A novel therapeutic approach gaining traction is radioligand therapy (RLT), a treatment that utilizes targeted radiolabeled molecules to deliver radiation directly to cancer cells. This [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">280029</post-id>	</item>
		<item>
		<title>Huntsman Cancer Institute Leaders Propel Theranostics Innovation to Revolutionize Cancer Treatment</title>
		<link>https://bioengineer.org/huntsman-cancer-institute-leaders-propel-theranostics-innovation-to-revolutionize-cancer-treatment/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Thu, 14 Aug 2025 22:20:51 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[cancer treatment revolution]]></category>
		<category><![CDATA[Huntsman Cancer Institute]]></category>
		<category><![CDATA[precision oncology]]></category>
		<category><![CDATA[radioligand therapy]]></category>
		<category><![CDATA[theranostics innovation]]></category>
		<guid isPermaLink="false">https://bioengineer.org/huntsman-cancer-institute-leaders-propel-theranostics-innovation-to-revolutionize-cancer-treatment/</guid>

					<description><![CDATA[Huntsman Cancer Institute at the University of Utah has announced a significant advancement in its approach to cancer treatment and research through the establishment of a dedicated leadership team for its burgeoning theranostics program. Theranostics, an innovative modality combining diagnostic imaging and targeted therapy, is rapidly transforming precision oncology by leveraging radiopharmaceuticals—radioactive compounds designed specifically [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">255750</post-id>	</item>
	</channel>
</rss>
